Erasca IPO Presentation Deck
July 2021, 46 slides
  1. Erasca
  2. Related Decks
  3. IPO Presentation Decks
corporate presentation | Erasca
| Erasca
offering summary | Erasca
our name is our mission to erase cancer | Erasca
leadership team has experience and drive to make a difference | Erasca
sab includes world leading experts in the ras pathway | Erasca
lives at stake annually with ras pathway alterations | Erasca
of unmet needs are blue ocean with limited no treatment options | Erasca
our singular focus is on the ras pathway | Erasca
deep modality agnostic ras pathway focused pipeline | Erasca
our pipeline targets every node on the ras pathway | Erasca
companies with common cause of targeting ras to defeat cancer eras corm | Erasca
as the most distal node within ras pathway is a critical target | Erasca
eras is a promising inhibitor in a field marked by attrition | Erasca
we believe eras is the most potent inhibitor in development | Erasca
eras uniquely long target residence time may enable dosing flexibility | Erasca
competitive inhibitors are more robust in shutting down | Erasca
other plus inhibitor combinations mask i a a i a foe a | Erasca
eras showed strong in combination activity in | Erasca
eras showed strong in combination activity in | Erasca
eras showed strong in activity in kras mutant models | Erasca
eras phase responses observed in patients with ras and alterations in diverse tumor types with single agent schedule | Erasca
swimmer plot demonstrated encouraging duration of treatment | Erasca
examples of single agent clinical activity of eras responses in melanoma and salivary gland adenocarcinoma pease | Erasca
eras schedule was better tolerated than | Erasca
eras recommended dose was well tolerated with minimal grade and no grade | Erasca
phase data showed is preferable to dosing simulations suggest bid dosing may improve profiles and even more | Erasca
is a critical on off switch that activates bound kras signaling | Erasca
eras demonstrated biochemically potent and selective inhibition | Erasca
eras showed superior potency to across cell lines a esophageal | Erasca
eras also showed superior potency to across cell lines | Erasca
eras demonstrated favorable physicochemical and properties which support its development as a combination therapy | Erasca
combination of eras eras showed strong in activity in kras mutant models | Erasca
era | Erasca
| Erasca
eras first in human study | Erasca
| Erasca
at turned kras from to | Erasca
we have discovered promising penetrant kras candidates i | Erasca
| Erasca
| Erasca
beyond targeting kras and other ras mutations | Erasca
our franchise programs are highly differentiated | Erasca
tissue specific and tissue agnostic trials target multiple indications | Erasca
value inflection points with steady anticipated | Erasca
compelling investment thesis | Erasca
See More
Erasca
IPO Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Inhibitor
Cancer
Melanoma
Recent decks by Erasca
Investor Presentation
January 2024
Investor Presentation
November 2023
Investor Presentation
August 2023
See all presentations by Erasca (4 decks)
Related decks
Alkermes
Investor Day
March 2021
BioAtla
IPO
December 2020
Immatics
Results
October 2022
Compass Therapeutics
Investor Presentation
May 2022
Boundless Bio
IPO
March 2024
Exscientia
Investor Presentation
October 2023
AstraZeneca
Investor Day
June 2021
Exscientia
Investor Presentation
August 2023
Recent decks by Erasca
See all presentations (4 decks)
Investor Presentation
January 2024
Investor Presentation
November 2023
Investor Presentation
August 2023
Alkermes
Investor Day
March 2021
BioAtla
IPO
December 2020
Immatics
Results
October 2022
Compass Therapeutics
Investor Presentation
May 2022
Boundless Bio
IPO
March 2024
Exscientia
Investor Presentation
October 2023
AstraZeneca
Investor Day
June 2021
Exscientia
Investor Presentation
August 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io